Shark Tank-fame World’s Fastest Cooking Device On2Cook Secures Seed Funding Over 2 Million USD, Valuation Stands at 100 Crore
Inventor and Entrepreneur Sanandan (Sandy) Sudhir, who created quite some ripples in Shark Tank with the world’s fastest cooking device, has declared that his startup On2Cook India Pvt Ltd has secured seed funding of over 2 Million USD. The funding round was led by angel investor Dr Mayur Desai, who infused the first tranche of Rs 16 crore for 16% equity, reaffirming the startup’s valuation at 12.5 Million USD. The round also saw the participation of NRI investor Nirbhay Gandhi. On2Cook is currently making an appearance at GulfHost 2022 at World Trade Centre in Dubai.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221109005461/en/
(L-R) Sanandan Sudhir, CEO & Founder On2Cook, Investor Shaival Desai from Desai family office (Photo: Business Wire)
“On2Cook works on the combination cooking technology with induction or flame acting on the food from outside and microwaves from inside. Engineered to disrupt the food industry, the product is designed to help both domestic as well as commercial kitchens save up to 70% on time and 50% on energy. Additionally, the food cooked retains water-soluble nutrients while preserving colour, texture and consistency. After being granted patents across India, US and UK, our invention stands to create a new product category in the kitchen space,” said On2Cook India Founder and CEO Sanandan Sudhir. He added that the brand is in talks with other strategic investors to raise another INR 3 crore as part of the round.
Echoing the sentiments, Shaival Desai from the Desai family office added, “There hasn't been a technological shift in the cooking appliances space in the post-industrial world for decades, if not centuries. On2Cook brings cooking into the 21st century. We are happy to join forces with Sanandan in his tryst to usher in a landmark transition in an industry, and even in the lifestyle of everyone.”
On2Cook has won several prestigious awards globally such as iF Design award, British Invention Show - Diamond Award for best International Invention and was the most celebrated Invention at CES, Las Vegas 2022. The device has been tested with more than 100 chefs and culinary experts across the globe. It can be used to cook everything from french fries, chicken to a cake with the softest base. Alongside ensuring faster and better quality food at a much economical price point, On2Cook makes cooking a seamless affair with app connectivity and eventually making the cognitive load negligible.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005461/en/
Contact information
Sanandan (Sandy) Sudhir
On2Cook India Pvt Ltd.
Sandy@on2cook.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Daiichi Sankyo Shines a Light on Inequalities and Unmet Needs in Care as Part of Its Commitment to People With Cardiovascular Disease31.8.2024 18:00:00 EEST | Press release
Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced its reinforced commitment to addressing key unmet needs and barriers in cardiovascular (CV) care, by shining a light on inequalities in treatment and outcomes experienced by various patient groups. The announcement follows the presentation of data from sub-analyses of the SANTORINI observational study and ETNA-AF (Edoxaban Treatment in routiNe clinical prActice in patients with nonvalvular Atrial Fibrillation) study programme, at the European Society of Cardiology (ESC) Congress 2024. Gender inequalities in CV disease treatment and LDL-C goal attainment Raised low-density lipoprotein cholesterol (LDL-C) is a key modifiable contributor to risk of cardiovascular major events. It has been shown that for every 1 mmol/L reduction in LDL-C, there is a 22% reduction in major cardiovascular events after 1 year.7,8 Female patients in Europe who are at high or very high CV risk were undertreated and less achieved guideline-recomm
Suzano completes purchase of 15% stake in Lenzing AG31.8.2024 01:40:00 EEST | Press release
Suzano, the world's largest pulp producer, today announces the completion of its acquisition of a 15% stake in Lenzing AG, the Vienna-listed leading global supplier of sustainable premium cellulosic fibres for the textile and non-wovens industry, from B&C Group. As announced in June this year, the transaction value is EUR 230 million (or EUR 39.70 per share). The agreement was subject to regulatory approval, which was granted without restrictions. The long-term partnership between Suzano and B&C Group establishes that Suzano has the right to hold two seats on Lenzing’s Board and the option to acquire an additional 15% stake from B&C Group until the end of 2028. Following the sale of the 15% stake, B&C Group now holds 37.25% of Lenzing’s share capital. Lenzing is a leading global supplier of premium wood-based cellulosic fibers (lyocell, modal, and viscose) for the production of clothing, home textiles, hygiene products, and non-woven materials. Beto Abreu, CEO of Suzano, said: “Lenzing
Ant International Collaborates with Brazilian Partners to Drive Financial Inclusion with Innovative Credit Tech Solutions30.8.2024 21:46:00 EEST | Press release
Ant International, a digital payment and financial technology leader, today announced its strategic initiative to provide AI-driven credit technology solutions designed to empower local partners and advance financial inclusions in Brazil. As a major milestone, Ant International has formed a strategic partnership with Dock, a leader in payments and banking technology in Latin America. This collaboration aims to enhance the credit management capability and infrastructure efficiency for Dock’s clients, which include financial institutions, retailers, fintech start-ups, etc. The shared vision is to make credit services more inclusive for market segments that are currently insufficiently served, such as micro, small and medium-sized enterprises (MSMEs). In the initial phase of the collaboration, Ant International’s AI-driven credit tech solutions, including an automated and intelligent risk management engine, will be explored for integration into Dock One platform. This initiative aims to s
Wipro Appoints Srikumar Rao as Global Head of Its Engineering Edge Business Line30.8.2024 17:20:00 EEST | Press release
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading technology services and consulting company, today announced the appointment of Srikumar Rao as Global Head of its Engineering Edge Business Line, effective from October 5, 2024. Srikumar succeeds Harmeet Chauhan, who is stepping down to pursue opportunities outside the organization. Srikumar will report to Srini Pallia. Srikumar has been with Wipro for 26 years and has grown with the organization, serving in various leadership roles. He was most recently the Chief Operating Officer (COO) of Wipro Engineering Edge (WEE) and Global Practice Head of Embedded Systems. His work has spanned several markets, selling and delivering specialized Engineering, Research, and Development (ER&D) services to Software & Internet, Semiconductor, Automotive, Manufacturing, and Communications clients. In his new role, Srikumar will continue to scale and strengthen Wipro’s engineering prowess. He will also be responsible for defining the vision
Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress30.8.2024 13:00:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced detailed results from the HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). The data were presented today in a Hot Line session at the European Society of Cardiology (ESC) Congress 2024, taking place August 30-September 2 in London, United Kingdom. Results from the HELIOS-B study were also simultaneously published in TheNew England Journal of Medicine. As previously reported, the HELIOS-B study met all 10 of its primary and secondary endpoints, across both the overall and monotherapy populations, with statistical significance. Enrolled patients were predominantly New York Heart Association (NYHA) Class I or II with wild-type disease and had been diagnosed by non-invasive methods, with substantial concurrent treatment with available standard of care treatments such as tafamidis and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom